A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic

Paliperidone palmitate 1-month (PP1M) and 3-month (PP3M) are long-acting injectable (LAI) antipsychotics that aim to enhance adherence, efficacy, tolerability and convenience of medication. Hospitalization rates, occupational status, treatment preference, satisfaction and caregiver burden of patients with schizophrenia has been assessed, and the advantages and disadvantages of PP1M vs. PP3M treatment has been evaluated in previous reports (Brasso et al. 2017; Einarson et al. 2017). With knowledge of patients' perspectives, healthcare providers could strengthen patient-provider relationships and better explore patients' reactions to changes in medication.
Source: Schizophrenia Research - Category: Psychiatry Authors: Tags: Letter to the Editor Source Type: research